期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 13, 期 11, 页码 1141-1159出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2013.853448
关键词
bipolar disorder; cariprazine; partial dopamine agonist; schizophrenia
资金
- Alkermes
- Bristol-Myers Squibb
- Eli Lilly
Cariprazine is a novel drug with partial agonist activity at dopamine D-2/3 receptors and six- to eightfold higher affinity for human dopamine D-3 over D-2 receptors. Results from several placebo-controlled Phase II/III trials in patients with a The Diagnostic and Statistical Manual of Mental Disorders IV diagnosis of schizophrenia or bipolar I disorder suggest that cariprazine is superior to placebo with respect to antipsychotic and antimanic activity. Reports concerning safety and tolerability of cariprazine are mainly favorable, although the rates of treatment-associated adverse events, which most commonly included akathisia and extrapyramidal symptom, are rather high. However, only minor alterations of clinical laboratory values, prolactin concentrations and ECG parameters are reported in cariprazine-treated patients. A new drug application to the U.S. F DA for cariprazine for the treatment of both schizophrenia and manic or mixed episodes associated with bipolar I disorder was submitted in November 2012. A more precise assessment of the clinical properties of this new drug will require additional studies, aimed to compare and contrast cariprazine with other antipsychotic agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据